I disagree, I think if you only had 10 or 100 participants, the data might not be very statistically accurate, but at 100 or 1000 (or the actual 98,000) people, the chance you're looking at a data anomaly is incredibly tiny. The official phase I and II trials contained smaller numbers of people, and are considered statistically valid enough to base a worldwide rollout upon.

When you say "less effective", remember you're talking about effectiveness at blocking symptoms once the vaccine recipient gets infected, not effectiveness at stopping transmission. As we're clearly seeing, these "vaccines" don't stop transmission.

It's 71% fully vaccinated. Nearly half of those testing positive are fully vaccinated.